acalabrutinib + calcium carbonate

Acalabrutinib + calcium carbonate refers to the coadministration of **acalabrutinib**, a highly selective, irreversible small molecule inhibitor of Bruton tyrosine kinase (BTK), and **calcium carbonate**, a commonly used antacid. The combination is not marketed under a unique brand name or as a fixed-dose product and is relevant solely in the context of drug-drug interaction. Acalabrutinib is primarily approved for the treatment of B-cell malignancies such as mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL)[1][5]. Calcium carbonate is used for acid-related gastrointestinal disorders and calcium supplementation. When coadministered, calcium carbonate can elevate gastric pH and significantly decrease the oral absorption and systemic exposure of acalabrutinib (AUC reduced by approximately 53%), which may compromise its clinical efficacy[1][2][4]. The reduction in acalabrutinib absorption is due to pH-dependent solubility, making it essential to separate administration by at least 2 hours if both are prescribed[1][4]. The combination is not intended for therapeutic synergy or additive clinical benefit; its relevance arises from a clinically significant pharmacokinetic interaction.

Brand names

Calquence (acalabrutinib)

Other names

calcium carbonate